MAP2K7 and leukemia: In 2011, McCubrey et al. [46] proposed that the Ras/Raf/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway contributes to the sensitivity and resistance of leukemia cells in response to chemotherapy.